We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Vivani Medical Inc (VANI) NPV

Sell:$1.05 Buy:$1.12 Change: $0.01 (0.91%)
Market closed |  Prices as at close on 22 February 2024 | Switch to live prices |
Change: $0.01 (0.91%)
Market closed |  Prices as at close on 22 February 2024 | Switch to live prices |
Change: $0.01 (0.91%)
Market closed |  Prices as at close on 22 February 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Vivani Medical, Inc. is a preclinical-stage biopharmaceutical company. The Company develops miniaturized and subdermal implants utilizing its NanoPortal technology to enable the delivery of a range of medicines to treat chronic diseases. It uses this platform technology to develop and commercialize drug implant candidates for the treatment of chronic disease and medication non-adherence. NanoPortal implant technology's initial focus is on peptide therapeutics for the treatment of patients with metabolic diseases. It operates through two segments: Biopharm Division and Neuromodulation Division. Its pipeline product candidates include NPM-119, NPM-159, NPM-139 and OKV-119. Its lead product, NPM-119, is a GLP-1 receptor agonist under development to treat patients with type two diabetes. NPM-159 is in feasibility testing for the treatment of non-alcoholic steatohepatitis (NASH). It is also in the development of neurostimulation systems to help patients recover critical body functions.

Contact details

United States
+1 (818) 8335000

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$54.60 million
Shares in issue:
51.03 million
Health Care Equipment
United States
US dollar

Key personnel

  • Adam Mendelsohn
    Chief Executive Officer, Director
  • Brigid Makes
    Chief Financial Officer
  • Truc Le
    Chief Operating Officer
  • Donald Dwyer
    Chief Business Officer
  • Lisa Porter
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.